February 05, 2009
Results of the ALLAY* study, published in Circulation, shows that Aliskiren is as effective as Losartan in reducing LV mass. The follow-up (after 36 weeks) also showed that Aliskiren proved equally effective in lowering blood pressure.
The study population, consisting of overweight hypertensive patients with LV hypertrophy**, was evaluated using the latest technology (MRI and ECG). Aliskiren is the first direct renin inhibitor that is orally active.
All study ECG´s*** have been evaluated by A+ Science in cooperation with Sahlgrenska University Hospital/Östra. Medical Advisor Dr Björn Dahlöf has contributed to planning and study design.
*Aliskiren in Left Ventricular Hypertrophy (ALLAY)
Effect of the Direct Renin Inhibitor Aliskiren, the Angiotensin Receptor Blocker Losartan, or Both on Left Ventricular Mass in Patients With Hypertension and Left Ventricular Hypertrophy (Solomon SD et al Circulation 2009;119:530-537)
**Left ventricular hypertrophy (LVH) is the thickening of the myocardium (muscle) of the left ventricle of the heart.
***A+ Science has extensive experience of ECG handling. Hundreds of thousands of ECG´s has been coded and evaluated in collaboration with Sahlgrenska University Hospital/Östra Core Laboratoryproducing essential results to a number of studies including, among others, LIFE (Dahlöf B et al Lancet 2002;359:995–1003) and ASCOT (Dahlöf B et al Lancet 2005;366:895–906).
Return to news list